For research teamsHelp me find a study
Back to all studies
TerminatedNCT03841773

TNX-102 SL for PTSD

This study was terminated in the United States. It is testing TNX-102 SL for PTSD.

PTSDDrugFrom 18 Years to 75 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether TNX-102 SL may be useful for adults experiencing ptsd.

What would participation involve?

Participants may receive TNX-102 SL, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.

Who is it mainly for?

This study appears to be mainly for adults with ptsd.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: March 7, 2019
Recruitment status
Terminated
Enrollment listed in the registry
192
Sponsor
Tonix Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT03841773
Official title
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P302)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT03841773. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

United States · 30 sites
  • Ashild Peters
    Phoenix, Arizona
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Little Rock, Arkansas
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Rogers, Arkansas
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Beverly Hills, California
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Oceanside, California
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Orange, California
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Panorama City, California
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Riverside, California
    Site status: Not listed — confirm with the team
  • Ashild Peters
    San Diego, California
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Temecula, California
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Colorado Springs, Colorado
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Norwich, Connecticut
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Washington D.C., District of Columbia
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Jacksonville, Florida
    Site status: Not listed — confirm with the team
  • Ashild Peters
    North Miami, Florida
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Orlando, Florida
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Tampa, Florida
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Alpharetta, Georgia
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Lincolnwood, Illinois
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Boston, Massachusetts
    Site status: Not listed — confirm with the team
  • Ashild Peters
    New Bedford, Massachusetts
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Flowood, Mississippi
    Site status: Not listed — confirm with the team
  • Ashild Peters
    St Louis, Missouri
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Las Vegas, Nevada
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Oklahoma City, Oklahoma
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Portland, Oregon
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Salem, Oregon
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Memphis, Tennessee
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Austin, Texas
    Site status: Not listed — confirm with the team
  • Ashild Peters
    Dallas, Texas
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

Based on the public registry summary, this study is trying to understand: This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine. Following successful screening and. The study team can confirm the exact objective and what it means for you.

Does this study involve a medication?

This appears to be a medication / drug study involving TNX-102 SL, Placebo SL Tablets. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with ptsd; age range: From 18 Years to 75 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Tonix Pharmaceuticals, Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.